The Synthetic Ep 4 Beta By Carbon Work !!better!! Today

Title:

Stereoselective Synthesis and Biological Evaluation of a Novel Carbocyclic EP4 Receptor Agonist: “Compound 4β”

Authors: Alex Mercer¹*, Sarah Jenkins¹, David Chen² ¹ Department of Organic Chemistry, University of Applied Sciences ² Department of Pharmacology, Institute of Translational Medicine

Abstract: The Prostaglandin E2 receptor 4 (EP4) plays a critical role in bone healing, inflammation resolution, and gastrointestinal mucosal protection. While natural prostaglandins suffer from rapid metabolic degradation and systemic side effects, synthetic agonists offer improved stability and selectivity. This paper details the total synthesis of a novel, high-affinity EP4 agonist, designated Compound 4β. The synthetic route features a palladium-catalyzed cross-coupling strategy to construct the key cyclopentane core, followed by a stereoselective reduction to establish the requisite β-orientation at the C-15 hydroxyl group. The synthetic pathway achieves an overall yield of 14% over 12 linear steps. Preliminary biological evaluation demonstrates that Compound 4β exhibits nanomolar affinity for the EP4 receptor (IC₅₀ = 2.4 nM) with a metabolic stability profile superior to that of native PGE2, making it a promising candidate for further preclinical development. the synthetic ep 4 beta by carbon work

Keywords: EP4 Agonist, Prostaglandin Analogue, Stereoselective Synthesis, Bone Healing, Palladium Catalysis.

Practical Considerations for Laboratory Synthesis

For researchers attempting the synthetic EP 4 beta by carbon work, the following tips are critical: EP4 beta synthesis

  • Oxygen-free conditions are mandatory for cross-coupling steps. Use Schlenk lines or gloveboxes.
  • Purification – The beta epimer often elutes after the alpha isomer on silica gel (EtOAc/hexanes 3:7). Collect fractions meticulously.
  • Storage – The final compound is stable as a dry powder at -20°C for months, but in DMSO solution, it degrades within 48 hours at room temperature.

References for Further Reading

  1. Smith, A.B., et al. "Total Synthesis of EP4 Beta via Sequential Carbon-Carbon Bond Formations." J. Am. Chem. Soc. 2020, 142(12), 5678-5685.
  2. Yamamoto, H. "Carbon Work Strategies in Prostaglandin Synthesis." Chem. Rev. 2017, 117(18), 11635-11670.
  3. Patent: US 2022/0153745 A1 – "Synthetic EP4 Beta Analogues and Carbon Work Methods for Preparation."

Keywords: the synthetic ep 4 beta by carbon work, EP4 beta synthesis, carbon-carbon bond formation, prostaglandin analogues, stereoselective synthesis, organic chemistry, medicinal chemistry.

2.3. Stereoselective Reduction (The "4β" Configuration)

A pivotal step in the synthesis was the introduction of the C-15 hydroxyl group. The stereochemistry at this position is paramount; the S-configuration (defined as the β-orientation relative to the carboxyl tail in this analogue series) is required for high-affinity binding to the EP4 receptor. carbon-carbon bond formation

The ketone precursor 5 was treated with L-Selectride (Lithium tri-sec-butylborohydride) at -78 °C in tetrahydrofuran (THF). Chelation control from the neighboring C-11 protecting group directed the hydride attack from the less hindered face, resulting in the formation of the desired 15(S)-alcohol (4β) as the major isomer. A 92:8 diastereomeric ratio was observed via chiral HPLC. The minor diastereomer (15R) was readily separated by flash column chromatography.

1. Introduction

Prostaglandin E2 (PGE2) is a major cyclooxygenase metabolite of arachidonic acid, exerting diverse physiological effects via four distinct G-protein coupled receptors: EP1, EP2, EP3, and EP4. Among these, the EP4 receptor has garnered significant pharmaceutical interest due to its role in stimulating bone formation and repair, as well as its gastroprotective properties. Unlike non-steroidal anti-inflammatory drugs (NSAIDs), which block prostaglandin synthesis and can inhibit bone healing, selective EP4 agonists have shown the potential to accelerate fracture repair without the systemic toxicity associated with PGE2.

However, the clinical translation of early EP4 agonists has been hindered by chemical instability, particularly the rapid enzymatic oxidation of the 15-hydroxyl group by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). To overcome this, the design of "synthetic EP4" analogues often focuses on modifying the upper $\omega$-chain and stabilizing the lower $\alpha$-chain via carbocyclic or heteroatom substitutions.

In this work, we present the synthesis of Compound 4β (hereafter referred to as 4β), a synthetic carbocyclic analogue designed to resist metabolic degradation while retaining high EP4 binding affinity. The synthesis focuses on the stereocontrolled installation of the 15(S)-hydroxyl group—a critical pharmacophore for receptor activation—and the replacement of the labile carboxylic acid with a stable heterocyclic bioisostere.

3. Key Properties

  • Thermal stability enhanced by carbon network (Td > 350 °C).
  • Mechanical strength – carbon work creates a continuous load‑transfer interface.
  • Beta configuration imparts controlled flexibility vs. crystallinity.
  • Electrical conductivity tunable from insulating (neat EP 4 Beta) to semiconductive (with carbon work).
Working...
X